European Union blocks Illumina’s years-long quest for Grail Walmart enlists UnitedHealth Group for 10-year value-based care partnership AmerisourceBergen's $19.8M deal with U.S. will expand shipments and distribution network of monkeypox meds Roche snaps up PD-1-focused Good Therapeutics for $250M; 'Sky's the limit' for spinout Philips recalls 17M CPAP and BiPAP machine masks due to potential magnet interference 'Podnosis': The changing landscape of femtech and health disparities for underserved populations GSK helps SpringWorks to double payday from boosted combo deal as it also reels $225M in new funding AstraZeneca, Merck's Lynparza rejected by NICE in prostate cancer over pricing—again $10,000 per test: Silicon Valley medtech exec convicted of fraud in COVID, allergy blood testing plot How Signify Health fits into CVS' healthcare strategy Brickell Biotech deviates from old plans, rebrands for fresh start Singapore sling: Catalent will invest $2.2M in clinical supply facility In Orbit: New Beam-buoyed biotech takes flight, gravitating toward the flash of RNA starlight Otolith Labs finds footing with $20M for vertigo-treating wearable Featured Story | By Conor Hale The European Commission said Illumina chose poorly when it decided to move forward with its $8 billion deal for the cancer test developer Grail. read more |
| |
|---|
|
Top Stories By Paige Minemyer Walmart is continuing its push into healthcare with the help of a powerful new partner: UnitedHealth Group. The two companies have agreed to a 10-year partnership that aims to drive value-based care adoption for Walmart's clinicians as well as launch a new Medicare Advantage plan. read more By Kevin Dunleavy With the monkeypox case count in the U.S. now more than 20,000 and infections spreading to more remote outposts, the Biden administration is bolstering its vaccine and treatment distribution effort with a contract with AmerisourceBergen. The deal will expand the number of weekly shipments and delivery locations of Bavarian Nordic’s Jynneos vaccine and Siga’s TYPOXX med. read more By Gabrielle Masson Roche has paid out $250 million cash to acquire Good Therapeutics as part of a bid to bolster its immuno-oncology efforts with the Seattle biotech's preclinical PD-1-regulated IL-2 program. read more By Andrea Park The trouble seemingly never ends for Philips’ beleaguered Respironics division. read more By Teresa Carey This week on "Podnosis," we talk about the changing landscape in the femtech sector after the Dobbs decision. We also chat about health policy issues that impact underserved patient populations. read more By James Waldron It’s a good day to be the CFO of SpringWorks Therapeutics. The precision medicine biotech has not only secured $225 million in funding, but also banked a further $75 million equity investment as part of an expanded agreement with GSK. read more By Zoey Becker Once again, England's drug cost watchdog has rejected AstraZeneca and Merck's Lynparza in prostate cancer after failing to reach a price agreement. The final decision created a rift between authorities in the U.K. read more By Conor Hale A federal jury said Mark Schena, president of Arrayit, misled investors and participated in a kickback scheme that covered more than $77 million in false orders for COVID-19 and allergy tests. read more By Paige Minemyer CVS Health has taken the first step in its bid to branch further into healthcare services with its acquisition of Signify Health, executives said Tuesday. read more By Gabrielle Masson Brickell Biotech is shedding its old name to pursue Fresh Tracks, rebranding in efforts to represent a potential evolution into a clinical-stage pharmaceutical company. read more By Kevin Dunleavy Catalent will expand its clinical supply facility in Singapore. A $2.2 million investment will provide an additional 31,000 square feet, representing a 20% increase in floor space. It will allow for the addition of 35 ultra-low temperature freezers. read more By Max Bayer A new biotech buoyed by Beam Therapeutics is taking flight, focused on RNA-based medicines. Orbital Therapeutics is launching with an undisclosed amount of money from top investors including a16z and Arch. read more By Andrea Park Otolith Labs is staying steady with a nerve-stimulating wearable device that aims to relieve the symptoms of chronic vertigo. It already has the FDA’s ear since earning the agency’s breakthrough designation last year. read more Resources Sponsored by: Genpact Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: ReachBio | The Cell Biology Experts™ How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: DocuSign Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: Blue Matter, strategic consultants in the life sciences This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: JLL Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
